Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 12/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3953934 | 1.00 | SLC6A2 (0.48) | SLC6A2CYP2D6CYP2C19NPSR1CHRM1 | |
| SCHEMBL3956015 | 1.00 | SLC6A2 (0.48) | SLC6A2CYP2D6CYP2C19NPSR1CHRM1 | |
| SCHEMBL27664327 | 1.00 | SLC6A2 (0.48) | SLC6A2CYP2D6CYP2C19NPSR1CHRM1 | |
| SCHEMBL3955051 | 0.93 | SLC6A2 (0.46) | SLC6A2HSD11B1MGLLL3MBTL3L3MBTL1 | |
| SCHEMBL3953255 | 0.89 | SLC6A2 (0.43) | SLC6A2CYP2D6CYP2C19NPSR1CHRM1 | |
| SCHEMBL3953408 | 0.89 | SLC6A2 (0.51) | SLC6A2HSD11B1MGLL | |
| SCHEMBL3953812 | 0.89 | SLC6A2 (0.46) | SLC6A2CHRM1 | |
| SCHEMBL3952423 | 0.88 | SLC6A2 (0.45) | SLC6A2CYP2C19CHRM1L3MBTL3L3MBTL1 | |
| SCHEMBL3955849 | 0.87 | L3MBTL3 (0.48) | CYP2D6CYP2C19NPSR1CHRM1L3MBTL3 | |
| SCHEMBL3960677 | 0.85 | SLC6A2 (0.47) | SLC6A2CHRM1TACR1L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050187251-A1 | Substituted N-heterocycle derivatives and methods of their use | WYETH (US) | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187251-A1 | Substituted N-heterocycle derivatives and methods of their use | MAOA, MAOB, SDHA | SLC6A2 71/4885CYP2D6 204/4885CYP2C19 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.